Twist Bioscience (TWST) Receivables - Net (2018 - 2026)

Twist Bioscience (TWST) has reported Receivables - Net for 9 consecutive years, with $64.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 28.44% year-over-year to $64.2 million; the TTM figure through Mar 2026 stood at $64.2 million (up 28.44% YoY), while the FY2025 annual figure was $57.0 million, up 63.36% from the prior year.
• Receivables - Net rose to $64.2 million in Q1 2026 per TWST's latest filing, from $50.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $64.2 million in Q1 2026 and bottomed at $32.0 million in Q2 2024.
• Historically, Receivables - Net has averaged $43.8 million across 5 years, with a median of $42.6 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 74.87% — and 2024, when it dropped 25.31%.
• Twist Bioscience's Receivables - Net stood at $44.4 million in 2022, then retreated by 20.44% to $35.4 million in 2023, then climbed by 11.2% to $39.3 million in 2024, then rose by 27.34% to $50.1 million in 2025, then increased by 28.15% to $64.2 million in 2026.
• Business Quant data shows TWST's Receivables - Net at $64.2 million in Q1 2026, $50.1 million in Q4 2025, and $57.0 million in Q3 2025.